New oral drug EP395 tested for COPD safety

NCT ID NCT05572333

Completed Disease control Sponsor: EpiEndo Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial investigates the safety and tolerability of EP395, an oral capsule taken once daily for 12 weeks, in people with chronic obstructive pulmonary disease (COPD). The study includes 61 adults aged 45 and older and compares EP395 against a placebo. Researchers monitor side effects, vital signs, lab values, and heart activity to determine if the drug is safe enough for further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EP395
What this could lead to: If successful, EP395 could offer a new oral treatment option to help manage COPD symptoms and inflammation.
What could go wrong: This is an early-phase trial focused on safety, not effectiveness. The drug may not improve COPD outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD

Contacts and locations

Locations

Bradford Royal Infirmary, Clinical Research Facility

Bradford, BD9 6RJ, United Kingdom
IKF Pneumologie GmbH & Co. KG

Frankfurt, 60596, Germany
IKF Pneumologie GmbH & Co. KG Institut für klinische Forschung Pneumologie

Mainz, 55128, Germany
Medicines Evaluation Unit Ltd. (MEU)

Manchester, M23 9QZ, United Kingdom
Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH

Großhansdorf, 22927, Germany
Southampton University Faculty of Medicine

Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.